Prelude Therapeutics Inc Ordinary Shares PRLD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 79.65M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 20.85
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 79
- Website
- https://www.preludetx.com
Valuation
|
Metric
|
PRLD
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.64 |
Price/Sales | 20.85 |
Price/Cash Flow | — |
Price/Earnings
PRLD
Financial Strength
|
Metric
|
PRLD
|
|---|---|
Quick Ratio | 1.95 |
Current Ratio | 2.03 |
Interest Coverage | — |
Quick Ratio
PRLD
Profitability
|
Metric
|
PRLD
|
|---|---|
Return on Assets (Normalized) | −55.33% |
Return on Equity (Normalized) | −92.42% |
Return on Invested Capital (Normalized) | −74.32% |
Return on Assets
PRLD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|@Nj^PR | LOCK|NQhh | $122B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|c%F<z$ | LOCK|p%Zy | $70B | |||
| argenx SE ADR
ARGX
| LOCK|bRp<^Rr | LOCK|## | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|>rr#kzt | LOCK|cyH>P | $38B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|h?W^s! | LOCK|Q# | $36B | |||
| Moderna Inc
MRNA
| LOCK|G>%KfTh | LOCK|q> | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|>r!x$<? | LOCK|y?GH | $25B | |||
| Incyte Corp
INCY
| LOCK|<<Z@@z< | LOCK|rz | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|<TJ&%& | LOCK|%X | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|^XnQ!> | LOCK|yQ | $16B |
United States